Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ABMT for children AML: Italian experience. GITMO-AIEOP Groups.

G Meloni, M Vignetti, C Andrizzi

    Bone Marrow Transplantation
    |January 1, 1991
    PubMed
    Summary

    Autologous bone marrow transplantation (ABMT) shows promising results for children with acute myeloid leukemia (AML) in second remission, offering better outcomes than standard chemotherapy. Further research is needed for first remission cases.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Nutritional assessment and medical dietary therapy for management of obesity in patients with non-dialysis chronic kidney disease: a practical guide for endocrinologist, nutritionists and nephrologists. A consensus statement from the Italian society of endocrinology (SIE), working group of the club nutrition-hormones and metabolism; the Italian society of nutraceuticals (SINut), club ketodiets and nutraceuticals "KetoNut-SINut"; and the Italian society of nephrology (SIN).

    Journal of endocrinological investigation·2024
    Same author

    Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.

    Annals of hematology·2018
    Same author

    Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2017
    Same author

    Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.

    Leukemia·2016
    Same author

    Autologous Unpurged Bone Marrow Transplantation for Acute Non Lymphoblastic Leukemia in First Remission.

    Leukemia & lymphoma·2016
    Same author

    A New Combination of Idarubicin, Etoposide and Cytarabine in Untreated Acute Non-Lymphoblastic Leukemia.

    Leukemia & lymphoma·2016

    Area of Science:

    • Pediatric Hematology Oncology
    • Hematopoietic Stem Cell Transplantation
    • Acute Myeloid Leukemia Research

    Background:

    • Acute Myeloid Leukemia (AML) in children presents significant treatment challenges.
    • Autologous Bone Marrow Transplantation (ABMT) is a potential therapeutic option for pediatric AML.
    • Evaluating different conditioning regimens is crucial for optimizing ABMT outcomes.

    Purpose of the Study:

    • To analyze the efficacy of ABMT in pediatric AML patients in first and second remission.
    • To compare outcomes based on various conditioning regimens used in ABMT.
    • To assess the role of ABMT in high-risk pediatric AML patients.

    Main Methods:

    • Retrospective analysis of 93 Italian children under 14 with AML in first or second complete remission (CR).

    Related Experiment Videos

  • Patients underwent ABMT with conditioning regimens including BAVC, TBI + CHT, or HD CHT.
  • Data collected on relapse rates and disease-free survival (DFS) at specified time points.

    • Main Results:

    • In first CR, overall DFS was 39% at 66 months, with TBI + CHT showing better DFS (61% at 48 months) than BAVC (35% at 66 months).
    • In second CR, overall DFS was 59% at 65 months, with TBI + CHT demonstrating superior DFS (65% at 65 months) compared to BAVC (56% at 50 months).
    • ABMT in second CR yielded significantly better results than standard chemotherapy alone.

    Conclusions:

    • ABMT in second CR for pediatric AML patients demonstrates superior outcomes compared to conventional chemotherapy.
    • While results in first CR require further investigation due to study heterogeneity, ABMT is a valuable option for high-risk pediatric AML.
    • This study highlights the potential of ABMT in improving survival rates for specific pediatric AML populations.